AOD-9604: growth hormone's fat-burning half, on its own

AOD-9604 is the cleanest idea on the whole peptide menu. Take growth hormone — the hormone that, among other jobs, tells your body to burn fat — and cut away everything except the fat-burning part. No blood-sugar spike. No slow thickening of tissue. Just the one signal that tells fat cells to let go of what they’re storing.

If that fragment does in you what it did in the lab, it’s one of the best-designed molecules in the room. And there’s a reason a molecule from the early 2000s is suddenly getting a second look right now. Both halves of that — the promise and the catch — are worth your time.

The fat-burning signal, on its own

Here’s what it’s built to do. Growth hormone is powerful and messy: it burns fat, but it also raises blood sugar, drives cell growth, and thickens connective tissue over the years. AOD-9604 copies just the fat-burning tail-end of that hormone and leaves the growth-signalling parts behind. It’s synthetic — a lab-built version of one stretch of a hormone your body already produces, edited down to the single signal worth keeping.

And in the lab, the edit worked. Heffernan and the Monash University team, in a 2001 paper in the International Journal of Obesity, gave the fragment to obese mice. They burned more fat and lost weight against untreated controls. The clean part is what didn’t happen: unlike full growth hormone in the same animals, AOD-9604 didn’t spike their blood sugar and didn’t switch on the cell-growth machinery. It did the wanted thing without the unwanted ones. On paper, that’s close to the ideal fat-loss tool — the upside without the tax.

Why the timing suddenly matters

This is the part that makes an old molecule interesting again.

Semaglutide and tirzepatide — Ozempic, Mounjaro — work. People lose serious weight on them. But a real chunk of what comes off isn’t fat, it’s muscle. Arora and colleagues, in a 2026 review in the Journal of Clinical Medicine, map out exactly this problem and the hunt it has kicked off: drugs that strip weight but take lean mass with it, and the search for something that protects the muscle while the fat goes.

Sit with what that means. Losing fat while keeping muscle is the entire game — it’s the difference between getting leaner and just getting smaller. The drugs everyone’s on don’t do it cleanly. A molecule that burns fat without laying a finger on muscle is exactly the tool this moment is asking for. AOD-9604’s whole design points at that gap. That’s a genuinely exciting place for a molecule to be sitting.

How far the proof actually goes

Now the catch, because the promise has one and we’re not going to bury it.

The clean mouse result is where the easy part ends. An Australian company, Metabolic Pharmaceuticals, took AOD-9604 into human obesity trials in the early 2000s, and the first-phase signal looked promising — Wilding’s 2004 update in Current Opinion in Investigational Drugs reported short-term weight loss in obese adults from that early work. Then came the bigger, longer trial — the one that actually decides whether a drug is real. It missed its target. The weight loss wasn’t enough to matter, Metabolic shut the obesity programme down, and in the twenty years since, no one has taken AOD-9604 to a final-stage trial. The mouse magic didn’t scale to people the way everyone hoped — that’s the honest headline, and it’s the one the research-chemical sites leave out.

Since then the molecule has had two quieter lives. One is a joint study: Kwon and Park, 2015, in Annals of Clinical and Laboratory Science injected AOD-9604 into the arthritic knees of thirty-two rabbits and saw less cartilage damage than in the saline group. A real result — in rabbits, with no human version run since. The other is the muscle-preservation idea above, which is still mechanism and hope, not human proof. And what’s sold online today runs ahead of all of it: Mendias and Awan, 2026, in Sports Medicine name AOD-9604 among a batch of peptides marketed straight to patients while the rigorous human safety data is still missing.

So the honest position is this: the design is beautiful, the animal data is real, and the one thing that would settle it — a proper modern human trial — has never been run. The mechanism earns the interest. It hasn’t yet earned the certainty. Fund that trial and let it read out well, and this stops being a promising fragment and becomes a real drug. Everything rides on a study nobody has paid for yet.

Where the FDA landed

AOD-9604 has already had its turn in front of the regulators. That’s the part most write-ups skip. It isn’t on the FDA’s July 2026 Pharmacy Compounding Advisory Committee wave — that round covers a different set of peptides — because its review already happened. PCAC looked at AOD-9604 on December 4, 2024 and voted against adding it to the list of substances pharmacies can legally compound. The stated reasons were the familiar ones: not enough human safety data, and no reproducible proof it works outside small trials.

What a PCAC vote actually decides for your access is a longer story, told in what a PCAC review actually is. The short version: the door to a legal, compounded AOD-9604 isn’t open, and the last official vote went the wrong way. Anyone using it today is buying through research-chemical channels, outside any supervision.

Anti-doping is simpler. AOD-9604 comes from growth hormone, and WADA treats that family as prohibited. If you’re tested, assume it’s banned and check the current code on the day.

What we’re building

The version of AOD-9604 worth being excited about isn’t a vial off a website with a twenty-year-old mouse study taped to it. It’s the trial nobody has run yet — this molecule tested properly in people, in the GLP-1 era it looks built for — and, if that reads out well, a physician writing a real prescription, a licensed US pharmacy compounding it, an assay on every batch before it ships.

Wolverine Health exists to be that legitimate version, once the science and the law both catch up. Neither has yet. That’s the plain reason we’re not selling you anything now. Put your email in below and we’ll flag you the moment the trial that could revive this molecule gets funded — and the moment a supervised, tested version becomes something you can actually get.